September 12, 2025 7:58am

A hope and a prayer which could offer an uncertain mix of upcoming inflation pressures

Pre-Open Signals: 1 Positive, 1 Sell into Strength and 4 Negative indications

Also, my hang-up or same-old mantra, “every time I see a new high, I am of the opinion to say BYE. And it is Friday, the escape door. Also, if the market falls back into its sideways, choppy range, sector “positions” could be back struggling and suffer.”

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

The cell and gene therapy sector has seen a few too many fits and starts

Stock futures are mixed as rate-cut hopes send market to where …

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Thursday’s night’s … RMi Closing Bell: The merry-go-round … https://www.regmedinvestors.com/articles/14102

RMi Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Friday: The pre-open Dow futures are DOWN -0.20% or (-90 points), the S&P futures are DOWN -0.07% or (-5 points) and the Nasdaq futures are UP +0.06% or (+13 points)

Stock futures are mixed with a barely label on Friday, 9/12

European equities trade mixed,

Asia Pacific markets traded higher.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • All 3 major averages are up for the week, so far (Dow +1.56%, S&P 500 +1.63% and the Nasdaq +1.58%) …
  • Thursday: The Dow closed UP +617.08 points or +1.36%, the S&P closed UP +55.43 points or +0.85% while the Nasdaq closed UP +157.014 points or +0.72%
  • Wednesday: The Dow closed DOWN -220.42 points or -0.18%, the S&P closed UP +19.43 points or +0.30% while the Nasdaq closed UP +6.572 points or +0.03%
  • Tuesday: The Dow closed UP +196.39 points or +0.43%, the S&P closed UP +17.46 points or +0.27% while the Nasdaq closed UP +80.79 points or +0.37%
  • Monday: The Dow closed UP +114.09 points or +0.25%, the S&P closed UP +13.65 points or +0.21% while the Nasdaq closed UP +98.311 points or +0.45%
  • Friday: The Dow closed DOWN -220.43 points or -0.48%, the S&P closed DOWN -20.58 points or -0.32% while the Nasdaq closed DOWN -7.306 points or -0.03%
  • Last week, the Dow was lost -0.32%, the S&P 500 +0.33% and Nasdaq gained +1.14%.

Economic Data Docket: Friday’s consumer sentiment could offer uncertain mix of upcoming inflation pressures

 

Q3 – September, 1 holiday, 3 negative and 5 positive closes

  • August - 11 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Let ‘em ride, I see a “muddy” econ laden week – as Friday’s consumer sentiment release; yet, I see red after green as September advances, along with the usual ups, downs and just plain uncertainties

Although:

Vertex Pharmaceuticals (VRTX) closed up +$8.82 after Wednesday’s -$7.93, Tuesday’s +$1.23 and Monday’s -$0.87 with a negative -$1.87 or -0.47% pre-open

CRISPR Therapeutics (CRSP) closed up +$4.08 after Wednesday’s -$1.88 with a positive +$0.03 or +0.05% pre-open

BioNTech SE (BNTX) closed up +$3.31 after Wednesday’s -$1.09, Tuesday’s -$0.57 and Monday’s -$9.80 with a negative -$1.76 or -1.69% pre-open

Arrowhead Pharmaceuticals (ARWR) closed up +$0.83 after Wednesday’s +$1.16, Tuesday’s +$0.56 and Monday’s -$1.91 with a neutral pre-open – Sell into Strength

Sarepta Therapeutics (SRPT) closed up +$0.69 and Wednesday’s -$0.42 with a negative -$0.21 or -1.17%

Capricor Therapeutics (CAPR) closed up +$0.11 with a neutral pre-open - SELL

 

 

The BOTTOM LINE: A wing and a prayer ...

Econs matter in “this” market scenario; brace for inflation data this week with cracks in “our” universe … we are so dependent on econ “numbers” to our universe’s share pricing …

September is historically the worst month for equities … however, some ruts are coming or not?

  • Are tariffs more of an issue to the future, hope the Supreme Courts levels over-reaching state/federal courts?
  • Don’t forget about Fed governor Lisa Cook and her “mortgage fraud criminal referral to DOJ> issues of being fired or not?

September is in the front window: understand the “flow”

  • 9/11 – Thursday closed positive with 27 positive, 11 negative and 2 flats
  • 9/10 – Wednesday closed negative with 13 positive, 22 negative and 1 flat
  • 9/9 – Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 9/8 - Monday closed negative with 10 positive, 28 negative and 2 flats
  • 9/5 – Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats
  • 9/3 – Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 -Monday was a holiday

Earnings are in the rear-view mirror; 4 net incomes and 25 net losses of 29 releases

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.